Finanzas de Qiagen NV (QGEN)QGENQiagen NV

QIAGEN N.V. (QGEN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables and Related Revenues, accounting for 90.3% of total sales, equivalent to $445.00M. Another important revenue stream is Instrumentation. Understanding this composition is critical for investors evaluating how QGEN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, QIAGEN N.V. maintains a gross margin of 63.28%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 26.43%, while the net margin is 19.33%. These profitability ratios, combined with a Return on Equity (ROE) of 11.93%, provide a clear picture of how effectively QGEN converts its operational activities into shareholder value.

In the context of the broader market, QGEN competes directly with industry leaders such as PODD and GKOS. With a market capitalization of $9.43B, it holds a significant position in the sector. When comparing efficiency, QGEN's gross margin of 63.28% stands against PODD's 70.18% and GKOS's 81.67%. Such benchmarking helps identify whether QIAGEN N.V. is trading at a premium or discount relative to its financial performance.

Qiagen has shown consistent revenue growth, with Q3 2026 preliminary net sales reported at $548 million, indicating stability. The gross margin is strong at 63.28%, and net income for Q2 2026 was $103.4 million, reflecting solid profitability.